IP Library Granted Patent US 7,930,105
Granted Patent B2
US 7,930,105 · App. 11/946,835 · Granted Apr 19, 2011

Grading of breast cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,930,105
App. No.
11/946,835
Granted
Apr 19, 2011
Kind
B2
Abstract

Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer.

Claims (36)

1. A method to determine the grade of breast cancer cells in a sample from a human subject, said method comprising

assaying said sample for gene expression that is increased in grade III relative to grade I breast cancer, wherein said gene expression is assayed by synthesis of cDNA molecules from expressed RNA of the genes

RACGAP1 (Rac GTPase activating protein 1, chromosomal location 12p13.2-p13.1),

CENPA (centromere protein A (17kD), chromosomal location 2p24-p21),

RRM2 (ribonucleotide reductase M2 polypeptide, chromosomal location 2p25-p24), and

NEK2 (NIMA (never in mitosis gene a)-related kinase, chromosomal location 1q32.2-q41)

in said sample; and

comparing the expression of the genes, via the cDNA molecules, to the expression of said genes in reference samples of known human grade III breast cancer; and

identifying said sample as containing grade III breast cancer cells.

2. The method of claim 1 wherein said assaying comprises preparing RNA from said sample.

3. The method of claim 2 wherein said RNA is amplified by quantitative PCR.

4. The method of claim 2 wherein said RNA is amplified by reverse transcription PCR (RT-PCR).

5. The method of claim 1 wherein said assaying comprises determining gene expression by an array.

6. The method of claim 1 wherein said sample is a ductal lavage or fine needle aspirate sample.

7. The method of claim 6 wherein said sample is microdissected to isolate one or more cells suspected of being breast cancer cells and said assaying is of RNA in said isolated cells.

8. A method to determine the grade of breast cancer cells in a sample from a human subject, said method comprising

assaying said sample for gene expression that is decreased in grade I relative to grade III breast cancer, wherein said gene expression is assayed by synthesis of cDNA molecules from expressed RNA of the genes of

RACGAP1 (Rac GTPase activating protein 1, chromosomal location 12p13.2-p13.1),

CENPA (centromere protein A (17kD), chromosomal location 2p24-p21),

RRM2 (ribonucleotide reductase M2 polypeptide, chromosomal location 2p25-p24), and

NEK2 (NIMA (never in mitosis gene a)-related kinase, chromosomal location 1q32.2-q41)

in said sample; and

comparing the expression of the genes, via the cDNA molecules, to the expression of said genes in reference samples of known human grade I breast cancer; and

identifying said sample as containing grade I breast cancer cells.

9. The method of claim 8 wherein said assaying comprises preparing RNA from said sample.

10. The method of claim 9 wherein said RNA is amplified by quantitative PCR.

11. The method of claim 9 wherein said RNA is amplified by reverse transcription PCR (RT-PCR).

12. The method of claim 8 wherein said assaying comprises determining gene expression by an array.

13. The method of claim 8 wherein said sample is a ductal lavage or fine needle aspirate sample.

14. The method of claim 13 wherein said sample is microdissected to isolate one or more cells suspected of being breast cancer cells and said assaying is of RNA in said isolated cells.

15. The method of claim 1 , wherein the assaying of said sample further includes synthesis of cDNA molecules from expressed RNA of the gene BUB1 (budding uninhibited by benzimidazoles 1 (yeast homolog), chromosomal location 2q14).

16. The method of claim 8 , wherein the assaying of said sample further includes synthesis of cDNA molecules from expressed RNA of the gene BUB1 (budding uninhibited by benzimidazoles 1 (yeast homolog), chromosomal location 2q14).

17. The method of claim 15 , wherein the cDNAs of said genes are synthesized by quantitative PCR of said RNAs.

18. The method of claim 15 , wherein the cDNAs of said genes are synthesized by reverse transcription PCR (RT-PCR).

19. The method of claim 16 , wherein the cDNAs of said genes are synthesized by quantitative PCR of said RNAs.

20. The method of claim 16 , wherein the cDNAs of said genes are synthesized by reverse transcription PCR (RT-PCR).

Assignments (9)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 055818/0519 Recorded Apr 24, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: BIOTHERANOSTICS, INC.
Reel/Frame 075457/0572 →
SECURITY INTEREST Recorded Apr 5, 2021
From: BIOTHERANOSTICS, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 055818/0519 →
RELEASE OF SECURITY INTEREST Recorded Feb 22, 2021
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: BIOTHERANOSTICS, INC.
Reel/Frame 055357/0691 →
SECURITY INTEREST Recorded Apr 22, 2019
From: BIOTHERANOSTICS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
Reel/Frame 048960/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2014
From: ERLANDER, MARK; MA, XIAO-JUN; SGROI, DENNIS G; ERLANDER, MARK G; MA, XIAO JUN
To: THE GENERAL HOSPITAL CORPORATION; ARCTURUS ENGINEERING INC
Reel/Frame 033397/0117 →
CHANGE OF NAME Recorded Jul 26, 2014
From: ARCTURUS ENGINEERING INC
To: ARCTURUS BIOSCIENCE, INC
Reel/Frame 033397/0351 →
MERGER AND CHANGE OF NAME Recorded Jul 26, 2014
From: AVIARADX, INC.; BIOTHERANOSTICS, INC.
To: BIOTHERANOSTICS, INC.
Reel/Frame 033397/0361 →
CHANGE OF NAME Recorded Jul 26, 2014
From: ARCTURUS BIOSCIENCE, INC
To: AVIARADX, INC.
Reel/Frame 033419/0776 →
MERGER AND CHANGE OF NAME Recorded Jul 7, 2014
From: AVIARADX, INC.; BIOTHERANOSTICS, INC.
To: BIOTHERANOSTICS, INC.
Reel/Frame 033255/0206 →